Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis.

Conclusion. In most cases, tofacitinib had similar efficacy and discontinuation rates due to adverse events compared to biologic DMARDs. PMID: 28377787 [PubMed - in process]
Source: International Journal of Rheumatology - Category: Rheumatology Tags: Int J Rheumatol Source Type: research